Personalised cancer follow-up: risk stratification, needs assessment or both?



Watson E, Rose PW, Neal RD, Hulbert-Williams N, Donnelly PK, Hubbard G, Elliott J, Campbell C, Weller D & Wilkinson C (2012) Personalised cancer follow-up: risk stratification, needs assessment or both?. British Journal of Cancer, 106 (1), pp. 1-5.

First paragraph: There are approximately 2 million people now living with or beyond cancer in the UK (Maddams et al, 2009) and this number is increasing. Cancer survivors can experience physical, psychological and social consequences as a result of the disease and the treatments received (Jefford et al, 2008; Foster et al, 2009). The effects may be immediate, some of which will resolve and others may persist and become long-term. Late effects can also occur and the interval between the end of treatment and onset can range from a few weeks (e.g. lymphoedema after axillary node removal) to several years (e.g. heart disease following radiotherapy to the chest area). Problems will be individual to each patient due to a unique combination of circumstances including the site and stage of the cancer, the type of treatment(s) given, the age of the patient, genetic factors, concomitant co-morbidities, family and social circumstances, and personality traits.

British Journal of Cancer: Volume 106, Issue 1

Publication date03/01/2012
PublisherNature Publishing Group

People (1)


Dr Gill Hubbard

Dr Gill Hubbard

Reader, Health Sciences (Highland & W.Isles)